RxDoctor Payments Data

Marlena Lewis

Family · Albuquerque, NMNPI 1306545454

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.2% of the total across 129 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 23.1% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in NM with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$3,381in general payments, 2019–2025

Across 129 payments — averaging $26.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$782
  • Regeneron Healthcare Solutions, Inc.$385
  • Sanofi$360
  • Genentech USA, Inc.$290
  • Incyte Corporation$281
  • CSL Behring$236
  • plus $1K from 15 others

What the payments were for

  • Food & beverage$3,28697%
  • Education$953%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,381 in reported general payments places this provider in the 90th percentile of 1,080 family providers in New Mexico.

See all family providers in New Mexico

Most prescribed under Part D

DrugClaimsCost to plans & patients
Spiriva RespimatTiotropium Bromide37$20,244
Breo ElliptaFluticasone/Vilanterol20$8,824
Epinephrine38$8,507
SymbicortBudesonide/Formoterol Fumarate36$8,426
BreynaBudesonide/Formoterol Fumarate32$6,061
Incruse ElliptaUmeclidinium Bromide11$4,412
Arnuity ElliptaFluticasone Furoate20$4,044
Fluticasone Propionate HfaFluticasone Propionate21$3,678
Fluticasone-SalmeterolFluticasone Propion/Salmeterol16$3,214
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate11$2,609
Wixela InhubFluticasone Propion/Salmeterol19$2,118
Ipratropium Bromide66$1,949
Albuterol Sulfate HfaAlbuterol Sulfate63$1,435
Azelastine Hcl28$968
Montelukast Sodium71$894

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKBreo Ellipta, Incruse Ellipta, Arnuity Ellipta$189$17,28151 claims
AstraZenecaSymbicort$782$8,42636 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,080 family providers in New Mexico.

Other family in Albuquerque

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →